Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Postibrutinib outcomes in patients with mantle cell lymphoma.

Blood - 24 Mar 2016

Martin Peter, Maddocks Kami, Leonard John P, Ruan Jia, Goy Andre, Wagner-Johnston Nina, Rule Simon, Advani Ranjana, Iberri David, Phillips Tycel, Spurgeon Stephen, Kozin Eliana, Noto Katherine, Chen Zhengming, Jurczak Wojciech, Auer Rebecca, Chmielowska Ewa, Stilgenbauer Stephan, Bloehdorn Johannes, Portell Craig, Williams Michael E, Dreyling Martin, Barr Paul M, Chen-Kiang Selina, DiLiberto Maurizio, Furman Richard R, Blum Kristie A

Abstract excerpt

Despite unprecedented clinical activity in mantle cell lymphoma (MCL), primary and acquired resistance to ibrutinib is common. The outcomes and ideal management of patients who experience ibrutinib failure are unclear. We performed a retrospective cohort study of all patients with MCL who experienced disease progression while receiving ibrutinib across 15 international sites. Medical records were evaluated for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Agammaglobulinaemia Tyrosine Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphoma, Mantle-Cell

Share to Piperidines

Share to Proportional Hazards Models

Share to Protein-Tyrosine Kinases

Share to Pyrazoles

Share to Pyrimidines

Source

Identifiers

PMID: 26764355
DOI: 10.1182/blood-2015-10-673145

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Postibrutinib outcomes in patients with mantle cell lymphoma.PMID 26764355Read ↗

Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.Semantic proximity Read ↗

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.Semantic proximity Read ↗

Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE studySemantic proximity Read ↗

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.Semantic proximity Read ↗

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemiaSemantic proximity Read ↗

Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphomaSemantic proximity Read ↗

Cyclin-Dependent Kinase 5 Contributes to Bruton’s Tyrosine Kinase Inhibitor Resistance via the IRE1α/XBP1 Axis in Mantle Cell LymphomaSemantic proximity Read ↗

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.Semantic proximity Read ↗

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.Semantic proximity Read ↗

Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.